Description

Trading of Rights Entitlement for Vineet Laboratories Limited has been extended to January 27, 2026, with the issue closing date revised to January 30, 2026.

Summary

The National Stock Exchange of India has extended the trading period for Rights Entitlement of Vineet Laboratories Limited (Symbol: VINEET-RE) until January 27, 2026, at the request of the company. The Rights Issue Committee of the Board of Directors approved this extension on January 13, 2026, to benefit investors by providing additional time for on-market renunciation and subscription.

Key Points

  • Last date for on-market renunciation extended from January 16, 2026 to January 27, 2026
  • Issue closing date extended to January 30, 2026
  • Issue opened on January 01, 2026
  • Rights Entitlements were credited on December 26, 2025
  • Extension approved by the Rights Issue Committee meeting held on January 13, 2026
  • Meeting duration: 12:00 Noon to 1:00 PM

Regulatory Changes

No regulatory changes. This is an operational extension of an existing rights issue timeline, approved under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Compliance Requirements

  • Eligible equity shareholders must ensure that off-market renunciation transfers are completed so that Rights Entitlements are credited to the Renouncee’s demat account on or before January 30, 2026 (Issue Closing Date)
  • Exchange members are informed to note the revised trading schedule for Rights Entitlement symbol VINEET-RE

Important Dates

  • Last Date for Credit of Rights Entitlements: December 26, 2025
  • Issue Opened: January 01, 2026
  • Last Date for On Market Renunciation: January 27, 2026 (Extended from January 16, 2026)
  • Issue Closes: January 30, 2026
  • Basis of Allotment: February 02, 2026
  • Allotment of Shares: February 02, 2026
  • Credit of Equity Shares: February 03, 2026
  • Listing of Shares: February 03, 2026

Impact Assessment

The extension provides eligible shareholders with an additional 11 days to make decisions regarding renunciation or subscription of rights entitlements. This operational adjustment reduces time pressure on investors and may improve participation rates in the rights issue. The extension has minimal market disruption impact as it only affects the timeline for this specific corporate action. Investors who have already renounced or subscribed are not negatively affected, while those who needed additional time benefit from the extended deadline.

Impact Justification

Extension of rights issue timeline affects existing shareholders and potential investors of Vineet Laboratories Limited, providing additional time for renunciation and subscription decisions.